Bausch Health as­serts push to 'vig­or­ous­ly' de­fend Xi­fax­an patent lit­i­ga­tion 

Bausch Health will con­tin­ue lit­i­gat­ing over its Xi­fax­an drug, threat­en­ing to ap­peal all the way up to the US Court of Ap­peals for the Fed­er­al Cir­cuit.

The Que­bec-based com­pa­ny, through its gas­troen­terol­o­gy busi­ness Sal­ix Phar­ma­ceu­ti­cals, said it will file an ap­peal if the fi­nal or­der is con­sis­tent with an oral or­der in a Delaware dis­trict court last week cen­tered around a case against Nor­wich Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER